^
    Back
    Association details:
    Biomarker:TP53 R280K + BRCA wild-type
    Cancer:Triple Negative Breast Cancer
    Drug:eprenetapopt (APR-246) (p53 reactivator)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASCO 2023
    Title:

    The combination of APR-246 and carboplatin in olaparib-resistant high grade serous ovarian cancer (HGSOC) and triple negative breast cancer (TNBC) cell lines.

    Published date:
    05/25/2023
    Excerpt:
    We selected two HGSOC (PEO1-S and Kuramochi-S) and one TNBC TP53 mutant cell lines (MDA-MB-231-S)....231-S harboured a TP53 mutation (mut) (missense R280K) and BRCA wildtype (wt), in PEO1-S BRCA2 mut p.Y1655* and TP53 mut was detectable. Kuramochi-S was TP53 mut (missense D816Y) and BRCA2 mut….The combination of APR246 and carboplatin is synergistic in all 3 studied cell lines but also in the OLA resistant ones.
    Secondary therapy:
    carboplatin
    DOI:
    10.1200/JCO.2023.41.16_suppl.e17504